

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-173)	LIRENTELIMAB
PRONUNCIATION	lir" en tel' i mab
THERAPEUTIC CLAIM	Treatment of eosinophilic gastrointestinal diseases, systemic mastocytosis, chronic urticaria, and/or severe allergic conjunctivitis

## CHEMICAL NAMES

1. Immunoglobulin G1, (anti-human CD19 (antigen)) (humanized clone RB4v1.2  $\gamma$ 1-chain), disulfide with humanized clone RB4v1.2  $\kappa$ -chain, dimer
2. Immunoglobulin G1-kappa, anti-(*Homo sapiens* Sialic acid-binding Ig-like lectin 8 (Sialoadhesin family member 2, Siglec-8, SAF-2)); humanized mouse monoclonal antibody;  $\gamma$ 1 heavy chain (1-450) [VH (*Homo sapiens* IGHV3-66\*01 (79%) –(IGHD)-IGHJ5\*01 (91%)/*Mus musculus* IGHV2-9\*02 (74%) –(IGHD)-IGHJ2\*01 (85%))] [8.7.14] (1-120) -*Homo sapiens* IGHG1\*03 {CH3[K107>del(450)]} (121-449)] (223-213')-disulfide with  $\kappa$  light chain (1'-213') [*Homo sapiens*/*Mus musculus* V-KAPPA (*Homo sapiens* IGKV3-11\*01 (86%) –IGKJ3\*01 (92%)/(*Mus musculus* IGKV4-57\*01 (77%) –IGKJ4\*01 (83%))] [5.3.15] (1'-106') -*Homo sapiens* IGKC\*01 (107'-213')], dimer (229-229":232-232")-bisdisulfide

## STRUCTURAL FORMULA

Heavy chain (N & N')							
EVLVESGGG	LVQPGGSLRL	SCAASGFSLT	IYGAHWVQRQA	PGKGLEWVGV	50		
IWAGGSTNYN	SALMSRFTIS	KDNSKNTVYL	QMNSLRAEDT	AVYYCARDGS	100		
SPYYYSMEYW	GQGTTVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	150		
DYFPEPVTVS	WNSGALTSKV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT	200		
YICNVNHNKPS	NTKVKRVEP	KSCDKTHTCP	PCPAPPELLGG	PSVFLFPPPKP	250		
KDTLMISRTP	EVTCVVDVDS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	300		
STYRVVSVLT	VLHQDWLNGK	EYCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	350		
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPV	400		
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK	450		
Light chain (N' & N'')							
EIVLTQSPAT	LSLSPGERAT	LSCSATSSVS	YMHWFQKPG	QAPRLLIYST	50'		
SNLASGIPAR	FSGSGSGTDF	TLTISSLEPE	DFAVYYCQQR	SSYPFTFGPG	100'		
TKLDIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWKVD	150'		
NALQSGNSQE	SVTEQDSKDS	TYSLSSTLTL	SKADYEKHKV	YACEVTHQGL	200'		
SSPVTKSFNR	GEC				213'		
Disulfide bridges location							
22-95	22"-95"	23'-87'	23'''-87'''	133'-193'	133'''-193'''	147-203	147"-203"
213'-223	213'''-223'''	229-229"	232-232"	264-324	264"-324"	370-428	370"-428"
Deleted residues							
<u>K</u>							
Lysines 450, 450'							
Glycosylation sites ( <u>N</u> )							
Asn-300 Asn-300'							

MOLECULAR FORMULA	C <sub>6408</sub> H <sub>9884</sub> N <sub>1700</sub> O <sub>2006</sub> S <sub>46</sub> . (non glycosylated)
MOLECULAR WEIGHT	144.31 kDa (non-glycosylated)
TRADEMARK	None as yet
SPONSOR	Allakos, Inc.
CODE DESIGNATIONS	AK002
<u>CAS</u> REGISTRY NUMBER	2283348-97-8
UNII	SWS48LJU3T
WHO NUMBER	11511

gbk